Table of Contents

2018 Month : April Volume : 7 Issue : 16 Page : 1949-1954

HEPATIC ENZYMES CHANGES IN CHRONIC KIDNEY DISEASE PATIENTS- A NEED FOR MODIFIED REFERENCE VALUES.

Omar B. Latiwesh1, Mustafa Y. G. Younis2, Srikumar Shakila3, Fatima Abdulmalik4, Jamal A. Alammari5, Yupa Min6, Azhar Hussain7, Jagannadha Rao Peela8

References :

1

Levey AS, Atkins R, Coresh J, et al. Chronic kidney disease as a global public health problem: approaches and initiatives – a position statement from Kidney Disease Improving Global Outcomes. Kidney Int 2007;72(3):247-59. http://www.kdigo.org/pdf/Levey_ KI_2007.pdf                      

CrossRef | Google Scholar | PubMed
2

Farag YM, Kari JA, Singh AK. Chronic kidney disease in the Arab world: a call for action. Nephron Clin Pract 2012;121(3-4):c120-c3. DOI: 10.1159/000345149.       

CrossRef | Google Scholar | PubMed
3

Levey AS, Andreoli SP, DuBose T, et al. Chronic kidney disease: common, harmful and treatable – World Kidney Day 2007. Am J Kidney Dis 2007;49(2):175-9.

CrossRef | Google Scholar | PubMed
4

Levey AS, Eckardt KU, Tsukamoto Y, et al. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney International 2005;67(6):2089-100.               

CrossRef | Google Scholar | PubMed
5

Ofsthun NJ, LaBrecque J, Keen M, et al. The association of mortality and hospitalization with hemoglobin (Hb) and missed dialysis treatments in stage 5 chronic kidney disease (CKD) patients with and without cardiac comorbidities. In: Nephrology dialysis transplantation. Oxford, England: Oxford University Press 2005.

6

Alashek WA. Epidemiology of dialysis-treated end-stage kidney disease in adults in Libya. PhD thesis, University of Nottingham 2013.           

7

Giannini EG, Testa R, Savarino V. Liver enzyme alteration: a guide for clinicians. Canadian Medical Association Journal 2005;172(3):367-79.       

CrossRef | Google Scholar | PubMed
8

Kratz A, Pesce M, Fink D. Appendix: laboratory values of clinical importance. Harrison's principles of internal medicine. 17th edn. 2012. http://www.accessmedicine. com/ content. Aspx.

9

Fabrizi F, Poordad FF, Martin P. Hepatitis C infection and the patient with end‐stage renal disease. Hepatology 2002;36(1):3-10.             

CrossRef | Google Scholar | PubMed
10

Kalantar-Zadeh K, McAllister CJ, Miller LG. Clinical characteristics and mortality in hepatitis C-positive haemodialysis patients: a population based study. Nephrology Dialysis Transplantation 2005;20(8):1662-9.             

CrossRef | Google Scholar | PubMed
11

Nakayama E, Akiba T, Marumo F, et al. Prognosis of anti-hepatitis C virus antibody-positive patients on regular hemodialysis therapy. Journal of the American Society of Nephrology 2000;11(10):1896-902.             

CrossRef | Google Scholar | PubMed
12

Fissell RB, Bragg-Gresham JL, et al. Patterns of hepatitis C prevalence and seroconversion in hemodialysis units from three continents: the DOPPS. Kidney International 2004;65(6):2335-42. 

CrossRef | Google Scholar | PubMed
13

Alashek WA, McIntyre CW, Taal MW. Hepatitis B and C infection in haemodialysis patients in Libya: prevalence, incidence and risk factors. BMC Infectious Diseases 2012;12(1): p. 265.                              

CrossRef | Google Scholar | PubMed
14

Rde SC, Lopea AA, Thome FS, et al. Chronic dialysis in Brazil: report of the Brazilian dialysis census, 2011. Jornal Brasileiro de Nefrologia 2012;34(3):272-7.                       

CrossRef | Google Scholar | PubMed
15

Huraib S, al-Rashed R, Aldrees A, et al. High prevalence of and risk factors for hepatitis C in haemodialysis patients in Saudi Arabia: a need for new dialysis strategies. Nephrology Dialysis Transplantation 1995;10(4):470-4.       

Google Scholar | PubMed
16

De Oliveira LIR, de Almeida LEP, De Mattos CMAG, et al. Liver enzymes in patients with chronic kidney disease undergoing peritoneal dialysis and hemodialysis. Clinics (Sao Paulo) 2012;67(2):131-4.                 

Google Scholar | PubMed
17

Ono K, Ono T, Matsumata T. The pathogenesis of decreased aspartate aminotransferase and alanine aminotransferase activity in the plasma of hemodialysis patients: the role of vitamin B6 deficiency. Clinical Nephrology 1995;43(6):405-8.         

Google Scholar | PubMed
18

Crawford DR, Reyna R, Weiner MW. Effects of in vivo and in vitro dialysis on plasma transaminase activity. Nephron 1978;22(4-6):418-22.  

CrossRef | Google Scholar | PubMed
19

Kovesdy CP, Ureche V, Lu JL, et al. Outcome predictability of serum alkaline phosphatase in men with pre-dialysis CKD. Nephrology Dialysis Transplantation 2010;25(9):3003-11.               

CrossRef | Google Scholar | PubMed
20

Eknoyan G, Lameire N. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int 2013;3(1):1-150.                            

CrossRef |
21

Levey AS, Coresh J, Balk E, et al. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification            

CrossRef | Google Scholar | PubMed
22

Hrstić I and Ostojić R. Chronic liver diseases in patients with chronic kidney disease. Acta Med Croatica 2011;65(4):349-53.              

Google Scholar | PubMed
23

Yasuda K, Okuda K, Endo N, et al. Hypoaminotransferasemia in patients undergoing long-term hemodialysis: clinical and biochemical appraisal. Gastroenterology 1995;109(4):1295-300.          

CrossRef | Google Scholar | PubMed
24

Mustafa LA, Al-Abachi SB, Khalaf DS. Some biochemical changes in serum of hemodialysis patients. Natl J Chem 2008;32:695-700.             

25

Ray L, Nanda SK, Chatterjee A, et al. A comparative study of serum aminotransferases in chronic kidney disease with and without end-stage renal disease: need for new reference ranges. International Journal of Applied and Basic Medical Research 2015;5(1):31-5.            

CrossRef | Google Scholar | PubMed
26

Fabrizi F, Lunghi G, Finazzi S, et al. Decreased serum aminotransferase activity in patients with chronic renal failure: impact on the detection of viral hepatitis. American Journal of Kidney Diseases 2001;38(5):1009-15.              

CrossRef | Google Scholar | PubMed
27

Lopes EP, Sette LH, Sette JB, et al. Serum alanine aminotransferase levels, hematocrit rate and body weight correlations before and after hemodialysis session. Clinics (Sao Paulo) 2009;64(10):941-5.             

CrossRef | Google Scholar | PubMed
28

Sette LHBC, de Almeida LEP. The reduction of serum aminotransferase levels is proportional to the decline of the glomerular filtration rate in patients with chronic kidney disease. Clinics (Sao Paulo) 2015;70(5):346-9. 

Google Scholar | PubMed
29

Huang JW, Yen CJ, Pai Mf, et al. Association between serum aspartate transaminase and homocysteine levels in hemodialysis patients. American Journal of Kidney Diseases 2002;40(6):1195-201.              

CrossRef | Google Scholar | PubMed
30

Hung KY, Lee KC, Yen CJ, et al. Revised cut-off values of serum aminotransferase in detecting viral hepatitis among CAPD patients: experience from Taiwan, an endemic area for hepatitis B. Nephrology Dialysis Transplantation 1997;12(1):180-3.            

Google Scholar | PubMed
31

Sette LH, de Almeida LEP. Liver enzymes serum levels in patients with chronic kidney disease on hemodialysis: a comprehensive review. Clinics (Sao Paulo) 2014;69(4):271-8.      

CrossRef | Google Scholar | PubMed
32

Magnusson P, Sharp CA, Magnusson M, et al. Effect of chronic renal failure on bone turnover and bone alkaline phosphatase isoforms. Kidney International 2001;60(1):257-65

CrossRef | Google Scholar | PubMed
33

Torres PU. Bone alkaline phosphatase isoforms in chronic renal failure. Kidney International 2002;61(3):1178-9.                      

CrossRef | Google Scholar | PubMed
34

Beddhu S, Ma X, Baird B, et al. Serum alkaline phosphatase and mortality in African Americans with chronic kidney disease. Clinical Journal of the American Society of Nephrology 2009;4(11):1805-10.           

CrossRef | Google Scholar | PubMed
35

Magnusson P, Degerblad M, Saaf M, et al. Different responses of bone alkaline phosphatase isoforms during recombinant insulin‐like growth factor‐I (IGF‐I) and during growth hormone therapy in adults with growth hormone deficiency. Journal of Bone and Mineral Research 1997;12(2):210-20.               

CrossRef | Google Scholar | PubMed